Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.500
-0.010 (-0.66%)
Dec 5, 2025, 4:00 PM EST - Market closed
Inhibikase Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -47.66 | -27.52 | -19.03 | -18.05 | -14.79 | -2.85 | |
| Depreciation & Amortization | 0.07 | 0.03 | 0.18 | 0.01 | - | - | |
| Stock-Based Compensation | 18.68 | 8.14 | 0.5 | 0.46 | 1.53 | 0.57 | |
| Other Operating Activities | -2.59 | - | 0.03 | 0.07 | 0.72 | 1.61 | |
| Change in Accounts Receivable | - | - | 0.04 | 0.07 | -0.11 | - | |
| Change in Accounts Payable | -1.45 | 0.27 | -0.5 | 0.06 | -0.63 | -0.25 | |
| Change in Unearned Revenue | - | - | - | - | -2.33 | 0.9 | |
| Change in Other Net Operating Assets | -0.03 | -0.07 | 0.7 | 0.04 | 1.3 | -1.11 | |
| Operating Cash Flow | -25.62 | -19.15 | -18.09 | -17.35 | -14.3 | -1.13 | |
| Capital Expenditures | -0.01 | - | -0.01 | -0.24 | - | - | |
| Investment in Securities | -36.16 | -37 | 11.67 | -15.76 | - | - | |
| Investing Cash Flow | -36.61 | -37 | 11.66 | -16.01 | - | - | |
| Long-Term Debt Issued | - | - | - | - | - | 0.27 | |
| Total Debt Issued | - | - | - | - | - | 0.27 | |
| Long-Term Debt Repaid | - | - | - | -0.25 | -0.04 | - | |
| Total Debt Repaid | - | - | - | -0.25 | -0.04 | - | |
| Net Debt Issued (Repaid) | - | - | - | -0.25 | -0.04 | 0.27 | |
| Issuance of Common Stock | 99.97 | 103.48 | 8.54 | 0.04 | 41.21 | 14.79 | |
| Repurchase of Common Stock | - | - | - | - | -0.08 | - | |
| Other Financing Activities | -0.39 | - | -0.14 | - | - | - | |
| Financing Cash Flow | 99.58 | 103.48 | 8.41 | -0.2 | 41.09 | 15.06 | |
| Net Cash Flow | 37.36 | 47.33 | 1.98 | -33.56 | 26.8 | 13.94 | |
| Free Cash Flow | -25.63 | -19.15 | -18.1 | -17.59 | -14.3 | -1.13 | |
| Free Cash Flow Margin | - | - | -6947.87% | -14253.37% | -461.10% | -161.69% | |
| Free Cash Flow Per Share | -0.30 | -0.81 | -3.00 | -4.17 | -4.71 | -0.82 | |
| Cash Interest Paid | - | - | - | 0 | 0 | 0.01 | |
| Levered Free Cash Flow | -13.18 | -8.93 | -12.17 | -10.97 | -9.47 | -1.49 | |
| Unlevered Free Cash Flow | -13.18 | -8.93 | -12.17 | -10.97 | -9.46 | -1.48 | |
| Change in Working Capital | -1.48 | 0.2 | 0.23 | 0.17 | -1.76 | -0.46 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.